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Aims The European Association of Cardiovascular Imaging (EACVI) Scientific Initiatives Committee performed a global





One-hundred and ten imaging centres from 37 countries across the world responded to the survey. Most non-
invasive investigations for coronary artery disease were widely available, except cardiovascular magnetic resonance
(available 40% centres). Coronary computed tomography angiography (CCTA) and nuclear scans were reported
by a multi-disciplinary team in only a quarter of centres. In the initial assessment of patients presenting with chest
pain, only 32% of respondents indicated that they rely on pre-test probability for selecting the optimal imaging test
while 31% proceed directly to CCTA. In patients with established coronary artery disease and recurrent chest
pain, respondents opted for stress echocardiography (27%) and nuclear stress perfusion scans (26%). In asymptom-
atic patients with coronary artery disease and an obstructive (>70%) right coronary artery stenosis, 58% of
respondents were happy to pursue medical therapy without further testing or intervention. This proportion fell to
29% with left anterior descending artery stenosis and 1% with left main stem obstruction. In asymptomatic patients
with evidence of moderate-to-severe myocardial ischaemia (15%), only 18% of respondents would continue medic-
al therapy without further investigation.
...................................................................................................................................................................................................
Conclusion Despite guidelines recommendations pre-test probability is used to assess patients with suspected coronary artery
in a minority of centres, one-third of centres moving directly to CCTA. Clinicians remain reticent to pursue a strat-
egy of optimal medical therapy without further investigation or intervention in patients with controlled symptoms
but obstructive coronary artery stenoses or myocardial ischaemia.
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Non-invasive imaging plays a critical role in the diagnosis, risk stratifi-
cation, and management of patients with chronic coronary syn-
dromes.1 Multiple different modalities can be used for patient
assessment, including stress echocardiography, coronary computed
tomography angiography (CCTA), and stress perfusion imaging using
cardiovascular magnetic resonance (CMR), single photon emission
tomography (SPECT), and positron emission tomography (PET).
However, there are concerns about the availability of these imaging
modalities and variation in reporting expertise across centres. The
recommended investigations and management of patients with
chronic coronary syndromes have been updated in the recent 2019
Guidelines on Chronic Coronary Syndromes [European Society of
Cardiology (ESC) Clinical Practice Guidelines].2 This document
aimed to provide clear recommendations, assisting healthcare pro-
viders in their clinical decision making when evaluating patients with
chronic coronary syndromes. The guidelines include recommenda-
tions on the imaging strategies that could be considered for patient
assessment and the role of non-invasive imaging in guiding manage-
ment. Previously the Clinical Outcomes Utilizing Revascularization
and Aggressive Drug Evaluation (COURAGE) trial3 and more recent-
ly the International Study of Comparative Health Effectiveness with
Medical and Invasive Approaches (ISCHEMIA) randomized con-
trolled trial have demonstrated that many patients with chronic cor-
onary syndromes can be managed safely with optimal medical
therapy alone.4
The aim of this survey from the European Association of
Cardiovascular Imaging (EACVI) Scientific Initiatives Committee5–9
was to evaluate current clinical practice in the assessment, investiga-
tion, and management of patients with suspected and confirmed
chronic coronary syndromes in light of the updated ESC clinical
guidelines and the most recent randomized controlled trial data.
Methods
The present survey was conducted by the EACVI Scientific Initiatives
Committee from the 30 April to the 1 June 2020 according to published
criteria (www.escardio.org/eacvi/surveys).5–9 Cardiology units in Europe
and around the world were invited to complete the easily accessible on-
line survey to describe the contemporary local use of cardiovascular
imaging modalities in the assessment of patients with chronic coronary
syndromes. The survey was also disseminated via social media. The 22
survey questions were designed based on the recent ESC guidelines on
the diagnosis and management of patients with chronic coronary syn-
drome. A number of questions incorporating clinical vignettes were
included to gain a better understanding of the clinical management of
challenging scenarios.
Results
In total, 110 centres from 37 different countries responded to the
survey. Responding centres were located in: Afghanistan (1),
Argentina (1), Austria (1), Belgium (2), Brazil (3), Croatia (1), Egypt
(1), France (2) Georgia (1) Germany (3), Greece (2), Hungary (1),
India (3), Italy (8), Japan (1), Lebanon (2), Lithuania (2), Malta (1),
Mexico (2), Republic of Moldova (1), Nepal (1), Netherlands (2),
New Zealand (2), North Macedonia (2), Norway (5), Poland (3),
Portugal (1), Russian Federation (1), Saudi Arabia (1), Serbia (5),
Slovenia (5), Spain (6), Switzerland (3), Thailand (1), Turkey (2), UK
and Northern Ireland (14), and USA (17). The majority of centres
were tertiary care hospitals or university centres (72%), followed by
secondary care or district hospitals (14%), private hospitals (9%), and
primary care centres (5%), Figure 1. The vast majority of respondents
were cardiologists (90%) and only 2% were radiologists.
Cardiac imaging availability and
reporting
The survey found that 96% of responding centres had access to at
least one form of non-invasive imaging for coronary artery disease
and, for the majority, it was easier to get a non-invasive test (69%)
than an invasive coronary angiogram (31%). The majority of respond-
ing centres had good access to stress echocardiography (85%),
CCTA (82%), and nuclear stress perfusion (SPECT or PET) scans
(71%), while stress CMR was only available in 40% (46% CMR avail-
ability in European centres and 30% in centres outside Europe)
Figure 1. Exercise electrocardiogram (ECG) testing was widely avail-
able (92%) although nearly half of respondents (46%) either did not
find this test useful at all (18%) or only rarely found it useful (28%).
Where available, stress CMR was reported by a multi-disciplinary
team in 43% of centres, with this proportion dropping to 28% for
CCTA and 27% for cardiovascular SPECT and PET scans (Figure 1).
Overall cardiologists were involved in reporting CCTA in 44% of
centres, CMR in 84% centres, and nuclear SPECT or PET scans in
42% centres.
Investigations in symptomatic patients
In patients presenting for the first time with chest pain, 32% of
respondents used a pre-test probability score to decide on the initial
diagnostic test, while 31% of respondents moved straight to CCTA
as the principal non-invasive test for decision making, 15% chose
stress echocardiography, 12% exercise ECG test, 5% nuclear stress
perfusion (SPECT or PET), and 4% stress CMR. Only 1% of centres
proceeded directly to invasive coronary angiography in the first in-
stance (Figure 2).
In patients with established coronary artery disease and recurrent
chest pain, stress echocardiography and nuclear stress perfusion
(SPECT or PET) scans were the preferred non-invasive tests for deci-
sion making in 27% and 26% of respondents, respectively. Invasive
coronary angiography was the next preferred option (17%), followed
by stress CMR (16%), CCTA (8%), and exercise ECG testing (6%),
Figure 2.
In patients with previous coronary artery bypass grafting (CABG)
and recurrent angina, one-fifth (20%) of responders indicated that
they opt for an initial strategy of medical therapy before considering
further imaging investigations. The preferred imaging tests in these
patients were invasive coronary angiography (28%), CCTA [24%, ei-
ther in isolation (11%) or in combination with stress imaging (13%)],
nuclear stress perfusion (SPECT or PET, 15%), stress echocardiog-
raphy (7%), and stress CMR (6%).
When patients require an assessment of myocardial viability, CMR
was the most commonly used technique (48%), followed by nuclear

















































.stress perfusion (SPECT or PET) imaging (22%) and stress echocardi-
ography (16%). Only 1% of respondents would rely on ECG findings
to assess viability while just 7% of respondents did not find viability as-
sessment useful in their practice.
Investigations in asymptomatic patients
When screening asymptomatic patients with no history of coronary
artery disease, more than half (58%) of survey responders would use
a clinical risk score to decide upon a primary prevention strategy.
This was either Systemic COronary Risk Evaluation (SCORE, 29% of
total number of respondents) or a local cardiovascular risk score
(29% of total number of respondents), Figure 3. Non-invasive imaging
was used to determine primary prevention strategies by 24% of sur-
vey respondents: CT calcium scoring (11%), CCTA (6%), stress
echocardiography (5%), and stress CMR (2%). The remaining 18% of
respondents rely on a combination of imaging and risk scores
(Figure 3).
In patients who are currently asymptomatic but have an estab-
lished history of coronary artery disease, the majority of respondents
(73%) would not perform routine non-invasive imaging tests but
would wait for recurrent symptom development to trigger further
imaging. The remainder 27% of respondents would use non-invasive
imaging modalities such as stress echocardiography (10%), stress
CMR (10%), CCTA (4%), or CT calcium scoring (3%) to track disease
progression (Figure 3).
Management of coronary artery disease
In asymptomatic patients with an obstructive lesion (defined as
>70% stenosis) in the right coronary artery, 58% would continue
medical therapy with no further tests, 28% request a stress test,
while 12% proceed to invasive coronary angiography and revascu-
larization. In a similar patient with an obstructive lesion in the prox-
imal left anterior descending coronary artery, 29% would continue
medical therapy, 36% would request a stress test, and 35% would
refer for invasive coronary angiography and revascularization
(Figure 4). Where an obstructive lesion is found in the left main
stem coronary artery on CCTA, 82% indicated that they would
refer this patient for invasive coronary angiography and revascula-
rization, while 10% would refer patients straight for CABG and
only 1% would continue medical therapy without further investiga-
tions (Figure 4).
Similarly, in a patient with controlled symptoms and mild reversible
ischaemia (8% ischaemic myocardium) in the anterior wall, 61% of
survey respondents would continue optimal medical therapy, while
one-fifth would perform a CCTA (22%) and 16% would proceed
straight to invasive coronary angiography and consider revasculariza-
tion. In contrast, moderate-to-severe ischaemia on stress myocardial
perfusion imaging (15% ischaemic myocardium) in the same patient
was an indication for continuing medical therapy in 18% of survey
respondents, with the same proportion (18%) opting for CCTA, and
63% proceeding straight to invasive angiography and revascularization
(Figure 4).
Figure 1 Central illustration summarizing survey findings showing the local availability of non-invasive imagining modalities for coronary artery
disease and local reporting of imaging tests. Doughnut chart showing the distribution of responding centres according to hospital setting
(72% university hospitals, 14% district hospitals, 9% private hospitals, and 5% primary care). Horizontal bar plot showing the availability of non-
invasive tests for coronary artery disease in the responding centres. Vertical bar plot showing the role of the reporting team according to the type
of non-invasive coronary imaging technique. CCS, chronic coronary syndromes; CCTA, coronary computed tomography angiography; CMR,
cardiovascular magnetic resonance; ECG, electrocardiogram; MDT, multi-disciplinary team.



















































This global survey provides insight into the contemporary use of car-
diac imaging in the assessment and management of patients with sus-
pected and confirmed coronary artery disease.
Cardiac imaging availability and
reporting
Encouragingly, most imaging modalities were available in the large
majority of centres, except CMR which was available in only 40% of
centres, (46% in Europe and 30% in centres outside Europe). The
EACVI recommendations on multi-modality imaging supports
reporting within a multi-disciplinary team bringing together expertise
from cardiologists, radiologists, and nuclear medicine specialists.10
However, multi-disciplinary reporting of CCTA and stress nuclear
scans was only performed in around a quarter of centres. Further
work is therefore required to improve the availability of CMR, to im-
prove adequate training,6 and to encourage the co-reporting of scans
by cardiologists, radiologists, and nuclear medicine experts.
Investigations in symptomatic patients
In patients presenting for the first time with chest pain, the 2019 ESC
guidelines recommend initial non-invasive assessment before referral
for invasive angiography.2 In this survey, the recommendations were
followed in 99% of responding centres. The guidelines also advocate
assessment of the pre-test probability of obstructive coronary artery
disease before deciding on subsequent investigation steps.
Interestingly, the current survey found that only one-third of centres
used pre-test probability assessments as recommended. In patients
presenting for the first time with chest pain, CCTA was the most
used non-invasive imaging technique, following its recent Class I rec-
ommendation in the ESC guidelines and reflecting recent randomized
controlled trial data.2,11 Equally, responding centres indicated that ex-
ercise ECG testing appears to be less frequently used in clinical prac-
tice with half of respondents indicating that they either do not find
this test useful at all or only rarely use it in the assessment of patients
with suspected coronary artery disease. This reflects a major shift in
clinical practice since the previous iteration of the ESC guidelines in
2013 when exercise ECG tolerance testing had a Class I and CCTA a
Class IIa indication.12
In patients with established coronary artery disease and recurrent
angina, stress imaging tests were preferred, with a quarter of
respondents using stress echocardiography and a quarter using stress
nuclear imaging in this scenario. One-sixth of respondents indicated
that they would proceed straight to invasive coronary angiography.
These results are broadly consistent with the current ESC guide-
lines,2 which emphasize/suggest stress imaging as the preferred initial
investigation method with invasive coronary angiography reserved
for high risk patients with refractory symptoms.
In patients with previous coronary artery bypass graft surgery and
recurrent angina, one-fifth of respondents indicated that they would
pursue an initial trial of medical therapy before further investigation.
Invasive coronary angiography was the preferred investigation in a
Figure 2 Investigations in symptomatic patients. Panel of two tree plots showing the proportion of different investigations for coronary artery
disease in patients presenting with chest pain for the first time (A) and for assessing symptomatic patients with known coronary artery disease (B).
CCTA, coronary computed tomography angiography; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; ICA, invasive coronary
angiography.



















































..quarter of survey respondents, while a similar proportion preferred
CCTA, either in isolation or alongside a functional test. Finally, CMR
was the preferred test for assessing myocardial viability, with the ma-
jority of respondents still finding viability assessments useful in clinical
practice despite the somewhat disappointing results of recent
randomized controlled trials.13
Investigations in asymptomatic patients
The use of non-invasive imaging in asymptomatic patients is more
controversial. In accordance with current guidelines,2 the majority of
respondents use cardiovascular risk scores to guide the prescription
of primary prevention intervention. However, 42% of respondents
indicated that they employ imaging, either in isolation or alongside
risk scores, to guide such decisions. While this proportion is perhaps
higher than expected, this strategy is supported by a Class IIb recom-
mendation in the ESC guidelines2 and requires further systematic
evaluation.
Periodic evaluation of symptom control, risk factor management,
and medication compliance should be standard practice in asymp-
tomatic patients with established coronary artery disease. However,
active monitoring of disease progression with imaging is not recom-
mended in asymptomatic patients. It is therefore perhaps surprising
that one quarter of survey respondents use imaging in this way.
Management of coronary artery disease
A key aim of this survey was to evaluate the contemporary manage-
ment of patients with established chronic coronary syndrome and
stabilized symptoms in the light of the ESC guidelines2 and recent
randomized controlled trial data.4 The clinical scenarios included in
this survey involved patients with asymptomatic chronic coronary
syndrome and an obstructive coronary lesion (>70%) or evidence of
myocardial ischaemia in whom subsequent investigation and manage-
ment decisions were mainly determined on prognostic grounds. The
poor prognosis associated with myocardial ischaemia and obstructive
stenoses has long dominated our approach to managing coronary ar-
tery disease. The updated ECS guidelines2 recommend revasculariza-
tion on prognostic grounds for patients with left main stem disease,
patients with reduced left ventricular rejection fraction (LVEF <_ 35%)
as a result of coronary artery disease, patients with a major coronary
vessel stenosis causing a significant intra-coronary pressure gradient
[fractional flow reserve (FFR) <_ 0.80 or instantaneous wave-free ratio
(iwFR) <_ 0.89], and in patients with a large ischaemic burden (>10%).
Previous evidence from the COURAGE randomized controlled trial3
and more recently the ISCHEMIA trial4 demonstrated that revascula-
rization does not reduce the risk of myocardial infarction or death in
patients with stable coronary artery disease on optimal medical ther-
apy, even in the presence of moderate-to-severe myocardial ischae-
mia. The association between myocardial ischaemia and a poor
prognosis might not therefore be causal.
This survey demonstrates the ongoing influence of the ischaemia
hypothesis in current clinical decision making. In patients with an ob-
structive right coronary artery lesion or a low ischaemic burden (not
considered prognostic in the ESC guidelines) and no ongoing symp-
toms, only 58–60% of respondents were happy to continue with
Figure 3 Investigations in asymptomatic patients. Panel of two tree plots showing the distribution of preferred screening modalities for coronary
artery disease (A) and monitoring disease progression in asymptomatic patients with stable coronary artery disease (B). CCTA, coronary computed
tomography angiography; CMR, cardiovascular magnetic resonance.



















































..medical therapy in the absence of any further tests or investigations.
This proportion dropped to 29% in patients with a left anterior
descending artery stenosis, suggesting that clinicians remain wary of
treating such patients conservatively. As the most recent results of
the ISCHEMIA trial continue to be evaluated and discussed, it will be
interesting to determine whether these attitudes change with time,
and the amount of downstream testing reduces. There was almost
universal agreement that patients with left main stem stenoses should
be revascularized on prognostic grounds, which is consistent with
both the guidelines and the exclusion of such patients from the
ISCHEMIA trial.4
Limitations
The overall number of survey respondents is relatively low, and the
majority worked in tertiary care centres or university hospitals. The
survey findings may therefore not be generalizable to other care envi-
ronments. The majority of survey respondents were cardiologists,
and therefore information on imaging practices and reporting may be
incomplete. Finally, there are differences between ESC and local na-
tional guidelines, which may have influenced the survey responses.
Conclusions
Pre-test probability for coronary artery disease is seldomly used in
clinical practice despite guideline recommendations. There is an
observed increasing trend in the use of non-invasive anatomical cor-
onary imaging (CCTA) to investigate patients with suspected
coronary artery disease, while stress testing remains the preferred
modality in patients with established coronary disease and recurrent
symptoms. In contemporary practice there remains significant vari-
ation in the investigation and management of asymptomatic patients
with chronic coronary syndrome who have obstructive coronary ar-
tery stenosis or myocardial ischaemia, in spite of repeated trial evi-
dence demonstrating the excellent clinical outcomes of patients
treated with optimal medical therapy alone.
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